Q2 Earnings Forecast for MacroGenics Issued By B. Riley

MacroGenics, Inc. (NASDAQ:MGNX - Free Report) - Analysts at B. Riley issued their Q2 2025 EPS estimates for shares of MacroGenics in a research note issued to investors on Monday, May 19th. B. Riley analyst M. Mamtani expects that the biopharmaceutical company will post earnings of ($0.49) per share for the quarter. B. Riley has a "Neutral" rating and a $3.00 price objective on the stock. The consensus estimate for MacroGenics' current full-year earnings is ($1.06) per share. B. Riley also issued estimates for MacroGenics' Q3 2025 earnings at ($0.17) EPS, Q4 2025 earnings at $0.72 EPS, FY2025 earnings at ($0.52) EPS, FY2026 earnings at ($1.41) EPS, FY2027 earnings at ($2.06) EPS, FY2028 earnings at ($1.59) EPS and FY2029 earnings at ($0.86) EPS.

Several other equities analysts have also recently issued reports on MGNX. Barclays restated an "overweight" rating and issued a $3.00 price target (down from $8.00) on shares of MacroGenics in a research report on Wednesday, May 14th. Stifel Nicolaus decreased their price objective on shares of MacroGenics from $6.00 to $5.00 and set a "hold" rating for the company in a report on Wednesday, May 14th. Wall Street Zen downgraded shares of MacroGenics from a "hold" rating to a "sell" rating in a research note on Thursday. Finally, HC Wainwright dropped their target price on shares of MacroGenics from $4.00 to $2.00 and set a "neutral" rating for the company in a research report on Tuesday, March 25th. One analyst has rated the stock with a sell rating, seven have issued a hold rating, two have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of "Hold" and a consensus target price of $6.13.

MacroGenics Trading Down 4.4%

NASDAQ MGNX traded down $0.07 during trading on Thursday, reaching $1.51. The company's stock had a trading volume of 273,887 shares, compared to its average volume of 799,201. The firm has a market capitalization of $95.27 million, a price-to-earnings ratio of -0.96 and a beta of 2.20. MacroGenics has a 12 month low of $0.99 and a 12 month high of $5.77. The firm has a 50 day moving average price of $1.49 and a 200 day moving average price of $2.53.

MacroGenics (NASDAQ:MGNX - Get Free Report) last posted its earnings results on Tuesday, May 13th. The biopharmaceutical company reported ($0.65) earnings per share for the quarter, missing the consensus estimate of ($0.61) by ($0.04). MacroGenics had a negative return on equity of 89.42% and a negative net margin of 69.07%. The firm had revenue of $13.19 million during the quarter, compared to analyst estimates of $9.59 million.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Armistice Capital LLC boosted its position in MacroGenics by 0.3% during the first quarter. Armistice Capital LLC now owns 6,296,000 shares of the biopharmaceutical company's stock worth $7,996,000 after purchasing an additional 20,000 shares in the last quarter. Wasatch Advisors LP boosted its holdings in MacroGenics by 37.6% in the fourth quarter. Wasatch Advisors LP now owns 3,488,493 shares of the biopharmaceutical company's stock valued at $11,338,000 after purchasing an additional 952,691 shares during the last quarter. Frazier Life Sciences Management L.P. boosted its holdings in MacroGenics by 5.5% in the fourth quarter. Frazier Life Sciences Management L.P. now owns 3,175,665 shares of the biopharmaceutical company's stock valued at $10,321,000 after purchasing an additional 164,938 shares during the last quarter. Acadian Asset Management LLC raised its stake in MacroGenics by 78.8% during the first quarter. Acadian Asset Management LLC now owns 2,308,649 shares of the biopharmaceutical company's stock valued at $2,923,000 after buying an additional 1,017,726 shares in the last quarter. Finally, Geode Capital Management LLC lifted its holdings in shares of MacroGenics by 1.9% in the 4th quarter. Geode Capital Management LLC now owns 1,433,217 shares of the biopharmaceutical company's stock worth $4,659,000 after purchasing an additional 26,341 shares during the last quarter. Institutional investors and hedge funds own 96.89% of the company's stock.

About MacroGenics

MacroGenics, Inc, a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens.